Laparoscopic Lateral Suspension With Mesh & Sacrocervicopexy for the Treatment of Uterine Prolapse
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03421457 |
|
Recruitment Status :
Completed
First Posted : February 5, 2018
Last Update Posted : March 18, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Pelvic Organ Prolapse Pelvic Floor Prolapse | Procedure: Uterus-preserving laparoscopic lateral suspension with mesh Procedure: Uterus-preserving laparoscopic sacrocervicopexy with mesh | Not Applicable |
Patient with uterine prolapse can participate in this study. A total of 44 women will be included. At random 22 patients undergo laparoscopic lateral suspension with mesh operation and 22 patients undergo laparoscopic sacrohysteropexy operation. Evaluation will take place during the surgery, at the postoperative visit after 4 weeks, 6th months and 12th months. Quality of life, degree of vaginal prolapse, safety, operation time and complications will be evaluated.
Subjective assessments will include Female Sexual Function Index (FSFI), Michigan Incontinence Severity Index (M-ISI), Prolapse Quality of Life questionnaire (PQoL), Pelvic Organ Prolapse Symptom Score (POP-SS) and Visual Analog Score (VAS).
Objective assessments will include routine gynecologic sonography, Pelvic Organ Prolapse Quantification System (POP-Q) and pelvic floor biometry measured by transperineal sonography.
Transperineal sonography will include those measurements:
Urethral rotation, Pelvic organ descent, Hiatal Diameter and the Anatomical localization of apex.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 44 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Care Provider, Outcomes Assessor) |
| Masking Description: | Care provider will be blind to the operation type. Outcomes will be assessed by a gynecologist who will be blind to the operation type, indications and complications. Assessor has wide experience in urogynecological sonography. |
| Primary Purpose: | Treatment |
| Official Title: | A Multicenter, Randomized, Prospective, Controlled Study Comparing Uterine Preserving Laparoscopic Lateral Suspension With Mesh Versus Laparoscopic Sacrocervicopexy in the Treatment of Uterine Prolapse: A Randomized Controlled Trial |
| Actual Study Start Date : | January 24, 2018 |
| Actual Primary Completion Date : | March 14, 2019 |
| Actual Study Completion Date : | March 14, 2019 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Lateral suspension
"Uterus-preserving Laparoscopic lateral suspension with mesh" technique will be performed in this arm.
|
Procedure: Uterus-preserving laparoscopic lateral suspension with mesh
V-shaped 2cm wide and 25cm length mesh strip is prepared from a 30x30cm Prolene mesh (Ethicon J&J).Deep dissection of the uterovesical space is performed.Cutaneous incisions are bilaterally made 3-4 cm superoposterior to the anterosuperior iliac spine.A grasper is introduced retroperitoneally through the sub-peritoneum holding the beginning part of mesh until reaching the vesicovaginal space in an oblique route rather than transverse.Round ligament is lifted upward and tunnel is practiced horizontally.Assistant grasper catches the distal mesh and pulls out through the opposite subperitoneal tunnel.Corner of mesh is fixed to the pubocervical fascia,uterine cervix and isthmus with Absorba-Tack™(Covidien, Mansfield,USA).Tension-free lateral mesh suspension is achieved at the desired level. |
|
Experimental: Sacrocervicopexy
"Uterus-preserving Laparoscopic sacrocervicopexy with mesh" technique will be performed in this arm.
|
Procedure: Uterus-preserving laparoscopic sacrocervicopexy with mesh
The peritoneum over the sacral promontory is incised until the anterior longitudinal ligament is reached and ureters are identified. Peritoneal relaxing incision is made medial to the right ureter, down into the pelvis, posterior to the cervix and rectovaginal fascia, laterally to the rectum. The arm of the mesh is sutured to the posterior cervix by 2.0 prolene and fixated to the sacral promontory by either Tacker (Covidien) and/or 2.0 prolene as tension-free. Complete peritonisation of the mesh is performed. |
- Change from baseline POP-Q measurements (mm) at 12th month. [ Time Frame: 12 months for each participant ]Prolapse degree; Point Ba/C/Bp
- Subjective Success - Change from baseline Female Sexual Function Index (FSFI) to measure sexual dysfunction at 12th month. [ Time Frame: 12 months for each participant ]Validated into Turkish language form will be used to compare preoperative and postoperative period. The FSFI is a multiple-trait scoring, self-report document used to assess female sexual function. It consists of 19 items that encompass six separate domains: desire, arousal, lubrication, orgasm, satisfaction, and pain. The maximum score is 36 points and the minimum score is 2 points. After completion of the questionnaire, the total SF score was calculated as follows: no sexual dysfunction (SD) (≥ 30 points) , mild SD (between <29 and > 23 points), and severe SD (≤ 22 points).
- Subjective Success - Change from baseline Michigan Incontinence Severity Index (M-ISI) to measure urinary incontinence at 12th month. [ Time Frame: 12 months for each participant ]Validated into Turkish language form will be used to compare preoperative and postoperative period. It has ten items, consisting of a total M-ISI domain (the sum of items 1-8) and a distinct Bother domain (the sum of items 9 and 10). The total M-ISI score consists of three subdomains (items 1-3 for stress urinary incontinence [SUI], items 4-6 for UUI, and items 7 and 8 for PU). The responses for each item range from 0 to 4 on a Likert-type scale, with higher values representing greater symptoms and greater bother. The total M-ISI domain ranges from 0 to 32, the Bother domain ranges from 0 to 8, the SUI and UUI subdomains range from 0 to 12, and the PU subdomain ranges from 0 to 8. Total domain and subdomain scores are obtained by simply adding the respective answers. The minimally important difference has been determined for the following domains/subdomains: total M-ISI (4 points), SUI (2 points), UUI (2 points), and PU (1 point).
- Subjective Success - Change from baseline Prolapse Quality of Life questionnaire (PQoL) to measure quality of life according to pelvic organ prolapse at 12th month. [ Time Frame: 12 months for each participant ]Validated into Turkish language form will be used to compare preoperative and postoperative period. he questionnaire included 20 questions grouped in sections (domains) related to a particular aspect of quality of life. A total of nine domains covering general health, prolapse impact, role limitations, physical and social limitations, personal relationships, emotional problems, sleep/energy disturbance as well as severity symptoms measurements were defined. Questions regarding bladder, bowel and sexual function were also separately included and validated for reproducibility and internal consistency. Responses ranged from 'none/not at all', through 'slightly/a little' and 'moderately' to 'a lot' to produce a four-point scoring system for each item. Scores in each domain ranged between 0 and 100 with a high total score indicating a greater impairment of quality of life.
- Subjective Success - Change from baseline Pelvic Organ Prolapse Symptom Score (POP-SS) to measure quality of life according to pelvic organ prolapse at 12th month. [ Time Frame: 12 months for each participant ]Validated into Turkish language form will be used to compare preoperative and postoperative period. Total range scores: 28 (min:0, max:28). Higher values represent a worse outcome.
- Subjective Success - Change from baseline Visual Analog Score (VAS) for pain at 12th month. [ Time Frame: 12 months for each participant ]Participant describes the pain related to the mesh. The respondent selects a whole number (0-10 integers) that best reflects the intensity of their pain with a format of a horizontal bar.
- Change from baseline Pelvic Hiatus measurements (mm) at 12th month. [ Time Frame: 12 months for each participant ]Anteroposterior hiatal length (mm)
- Change from baseline Pelvic biometry measurements at 12th month. [ Time Frame: 12 months for each participant ]Prolapse degree over symphysis pubis (mm) Anterior compartment over 10mm, Posterior compartment over 15 mm are clinically relevant
- Change from baseline bladder neck mobility measurements at 12th month. [ Time Frame: 12 months for each participant ]Urethral rotation (degree) between rest and valsalva maneuver states
- Failure (%) [ Time Frame: 12 months for each participant ]Failure is defined by any recurrence of prolapse, mesh erosion and need for additional surgery
- Complications [ Time Frame: 12 months for each participant ]Perioperative and postoperative complications including Severe bleeding, hematoma, bladder injury, bowel injury, ureter injury, vascular injury, nerve injury, abscess, lower urinary tract infections, mesh extrusion, mesh exposure, prolapse recurrence, De novo SUI/OAB, dyspareunia, pelvic pain
- Operation time [ Time Frame: Operation time will noted for each participant at the same day of the operation. Operation time will be determined with using a chronometer,from the time of first skin incision until the suturing the skin of the trocar entry, assessed up to 52 weeks. ]Duration of the operation between the first skin incision and suturing the skin of the trocar entries
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- >18 years old
- > Symptomatic prolapse of central compartment with a Pelvic Organ Prolapse Quantitative (POP-Q) stage 2 associated or not with anterior or posterior compartment prolapse.
- Patients who are not comfortable with using or refusing pessary
- Wish to preserve the uterus
Exclusion Criteria:
- Any cue for gynecologic oncological condition
- Patients who approves Le Fort colpocleisis among who does not have any sexual intercourse
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03421457
| Turkey | |
| Fatih Sultan Mehmet Training and Research Hospital, Sancaktepe Campus | |
| Istanbul, Sancaktepe, Turkey, 34785 | |
| Sisli Hamidiye Etfal Training and Research Hospital | |
| Istanbul, Sisli, Turkey, 34371 | |
| Study Director: | Niyazi Tug, As.Prof. | Chief of the Department |
| Responsible Party: | MURAT YASSA, Principal Investigator, Fatih Sultan Mehmet Training and Research Hospital |
| ClinicalTrials.gov Identifier: | NCT03421457 |
| Other Study ID Numbers: |
RCTPOPS |
| First Posted: | February 5, 2018 Key Record Dates |
| Last Update Posted: | March 18, 2019 |
| Last Verified: | March 2019 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Plan Description: | Study Protocol |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Pelvic Organ Prolapse Translabial ultrasound Transperineal ultrasound Lateral Mesh Suspension Descensus uteri Laparoscopic pelvic organ prolapse repair Uterus preserving hysteropexy |
uterine-preserving fertility-sparing sacropexy cervicopexy sacrocervicopexy sacrohysteropexy mesh prolapse surgery |
|
Uterine Prolapse Prolapse Pelvic Organ Prolapse Pathological Conditions, Anatomical Uterine Diseases |

